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Background: Breast cancer central nervous system (CNS) metastases are an increasingly important problem
because of high CNS relapse rates in patients treated with trastuzumab and/or taxanes.
Patients and methods: We evaluated data from 2887 node-positive breast cancer patients randomised in the BIG
02-98 trial comparing anthracycline-based adjuvant chemotherapy (control arms) to anthracycline–docetaxel-based
sequential or concurrent chemotherapy (experimental arms). After a median follow-up of 5 years, 403 patients had
died and detailed information on CNS relapse was collected for these patients.
Results: CNS relapse occurred in 4.0% of control patients and 3.7% of docetaxel-treated patients. CNS relapse
occurred in 27% of deceased patients in both treatment groups. CNS relapse was usually accompanied by neurologic
symptoms (90%), and 25% of patients with CNS relapse died without evidence of extra-CNS relapse. Only 20% of
patients survived 1 year from the diagnosis of CNS relapse. Prognosis of CNS relapse was worse for patients with
meningeal carcinomatosis when compared with brain metastases. Unexpected findings included a higher rate of
positive cerebrospinal fluid cytology (8% versus 3%) and more frequent use of magnetic resonance imaging for
diagnosis (47% versus 30%) in the docetaxel-treated patients.
Conclusion: There is no evidence that adjuvant docetaxel treatment is associated with an increased frequency of
CNS relapse.
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introduction
Node-positive breast cancer is a disease with a significant risk of
relapse and death. Anthracycline-containing adjuvant
chemotherapy has been shown to increase disease-free survival
(DFS) and overall survival [1-3]. Adjuvant chemotherapy and/or
endocrine therapy (for hormone receptor-positive patients) are
recommended to women with node-positive breast cancer after
surgery on the basis of a multitude of adjuvant trials summarised
in meta-analyses [1] and guidelines [2, 3]. The activity of
docetaxel in metastatic disease mandated its evaluation in the
adjuvant setting. In addition, the relative merits of combination
versus sequential anthracycline–taxane adjuvant chemotherapy
remain undefined. Similarly to other trials initiated in the 1990s,
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the BIG 02-98 trial randomised 2887 patients with node-positive
breast cancer into experimental taxane-containing arms versus
control arms. First efficacy results of the BIG 02-98 trial have
been reported [4]. At database cut-off in March 2006, median
follow-up was just >5 years and 732 events had occurred. The
addition of docetaxel resulted in a borderline improvement in
DFS {hazard ratio (HR) of 0.86 [95% confidence interval (CI) =
0.74–1.00; P = 0.051]}. However, the sequential docetaxel arm A
(doxorubicin)/ T (docetaxel)/ cyclophosphamide,
methotrexate, fluorouracil (CMF) produced superior DFS over
both the concurrent docetaxel arm AT/CMF (HR = 0.83; 95%
CI = 0.69–1.00) and a sequential control arm A/ CMF (HR =
0.79; 95% CI = 0.64–0.98).
The objective of the present analysis was to evaluate the
frequency of CNS relapse in patients treated with or without
adjuvant taxanes. This question was studied because taxane
treatment in advanced breast cancer was associated with high
CNS relapse rates in some studies (up to 30%) [5, 6].
patients and methods
The Breast International Group initiated the BIG 02-98 trial with the
participation of eight cooperative groups in 22 countries. The trial was open
to accrual from June 1998 to June 2001.
Patients with histologically proven node-positive breast cancer staged
T1–3, aged 18–70 years, resected with clear margins and containing at least
eight resected axillary lymph nodes were required to give written informed
consent before entering the study. Mastectomy could be followed by
radiotherapy while the latter was mandatory after breast-conservation
surgery. Endocrine therapy was given to all patients with oestrogen receptor
(ER) and/or progesterone receptor (PgR)-positive tumours after
chemotherapy. Exclusion criteria included evidence of metastatic breast
cancer assessed by chest X-ray, abdominal ultrasound or computed
tomography (CT) scan and bone scan; abnormal cardiac function assessed
by multiple uptake gated acquisition scan or echocardiography and a prior
cancer or major comorbidities.
The BIG 02-98 trial randomised 2887 node-positive breast cancer
patients into four arms of adjuvant chemotherapy: docetaxel given either
sequentially (A–T) or in combination (AT) with doxorubicin, followed by
CMF (experimental arms), in comparison to doxorubicin alone (A) or in
combination with cyclophosphamide (AC), followed by CMF (control
arms). Twice as many patients were randomly assigned into the
experimental arms (A–T or AT) than into the control arms (A or AC).
Randomisation was stratified by the following factors: centre, number of
positive nodes (1–3 versus 4+) and age (<50 versus ‡50).
The objective of the present report is to evaluate the frequency of CNS
relapse in patients treated with adjuvant docetaxel in comparison to
patients not treated with adjuvant docetaxel. We collected information on
CNS relapse in patients at the time of death. With a median follow-up of
62.5 months, patients who had died by March 2006 were included in this
analysis. An unknown number of patients who are still alive may have
experienced CNS relapse. These patients are not included in the current
analysis. The number of such patients is likely to be small, however, given
the median follow-up of 5 years and the dismal prognosis of patients who
experience a CNS relapse.
results
The characteristics of the patient population included in the
BIG 02-98 trial are summarised in Table 1 (intention-to-treat
population). The patients randomised to control (A or AC) and
experimental arms (A–T or AT) were well balanced with respect
to age, menopausal status, nodal status, tumour grade, tumour
size, as well as hormonal status and HER2 status.
The characteristics of the patient population analysed for
CNS relapse at the time of death are shown in Table 2. In the
control arms (A or AC), 143 patients (14.8%) had died, while
in the experimental arms (A–T or AT), 260 (13.5%) patients
had died. The rate of CNS relapse was 4.0% in the
nondocetaxel-treated (control) patients and 3.7% in the
docetaxel-treated (experimental) patients, with CNS being the
first site of relapse in 13 (1.3%) and 35 (1.8%), respectively.
Among patients deceased at the median follow-up of 5 years,
the rate of CNS relapse was 27% for both groups. Information
on CNS relapse was available for 393 (97.5%) of the 403
deceased patients.
Table 1. Patient population enrolled in the BIG 02-98 trial (N = 2887)
(intention-to-treat)
Treatment arm Control arms (no T) Experimental arms (T)
Treatment A or AC A–T or AT
n % n %
Patients 968 100 1919 100
Age
<50 years 520 54 1022 53
‡50 years 448 46 897 47
Menopausal status
Pre 518 53 1034 54
Post 393 41 780 41
Unknown 57 6 105 5
Nodal status
1–3 LNs 527 54 1045 54
4 or more 441 46 874 46
Tumour grade
Grade 1 90 9 161 8
Grade 2 403 42 855 45
Grade 3 432 45 832 43
Unknown 43 4 71 4
Tumour size
pT1 367 38 776 40
pT2 529 55 994 52
pT3 66 7 141 7
pTX 6 0.6 8 0.4
Hormone receptors
ER+/PgR+ 488 50 994 52
ER+/PgR2 112 12 230 12
ER2/PgR+ 44 4 73 4
ER2/PgR2 238 25 447 23
ER+/PgR unknown 80 8 158 8
ER2/PgR unknown 5 0.5 14 0.7
ER unknown 1 0.1 3 0.2
HER2 available 374 38.6 731 38.1
HER2+ 95 25.4 189 25.9
HER22 279 74.6 542 74.1
A, doxorubicin; AC, doxorubicin/cyclophosphamide; A–T, doxorubicin
followed by docetaxel; AT, doxorubicin combined with docetaxel; ER,
oestrogen receptor; PgR, progesterone receptor; HER2, human epithelial
(growth factor) receptor 2; LNs, lymph nodes; T, docetaxel.
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Endocrine responsiveness is known to be inversely related to
the rate of CNS relapse [7]. Similarly, in our series among all
patients entered in the trial, 44 of 2180 (2%) with hormone
receptor-positive tumours were documented with CNS relapse
compared with 66 of 707 (9%) of those with hormone
receptor-negative tumours. Among deceased patients, the
overall rate of CNS relapse was 66 of 181 (36.4%) with
hormone receptor-negative tumours compared with 44 of 222
(19.8%) with hormone receptor-positive tumours, while the
rates were not different between the treatment arms (Table 2).
The rates of CNS relapse were not different between
premenopausal patients (57 of 198, 28.8%) and
postmenopausal patients (46 of 178, 25.8%).
In recent years, high rates of CNS relapse have been described
in HER2-positive breast cancer patients treated with
trastuzumab [8-10]. Therefore, we analysed CNS relapse in
relation to HER2 status. HER2 analysis was carried out
centrally by immunohistochemistry after prospective collection
of tissue in the BIG 02-98 trial. Overall HER2 status is currently
available for 1105 (38.3%) of the 2887 study patients (Table 1).
HER2 positivity was defined as a 3+ intensity staining in at least
30% of malignant cells. HER2 positivity was distributed equally
across the treatment arms, with HER2-positive tumours in
25.4% of patients in the control arms and 25.9% in the
experimental arms (Table 1). In the patient population
analysed for CNS relapse (n = 403), HER2 results were available
in half of the patients (50.1%) (Table 2). CNS relapse was
significantly more frequent in patients with HER2-positive
tumours (33 of 64 = 51.6%) compared with patients with
HER2-negative tumours (48 of 133 = 36.1%, P = 0.039).
However, there were no differences in CNS relapse between the
standard arms and the experimental (docetaxel-containing)
arms according to HER2 status. In triple-negative disease (ER
negative, PgR negative and HER2 negative), the frequency of
CNS relapse overall was 50% (29 of 58), quite similar to HER2
positive disease, again with no difference between the arms
(Table 2).
Results on the 110 patients who experienced CNS relapse are
shown in Table 3. In both groups, almost all (90%) of these
patients had neurological symptoms. As expected, the vast
majority of CNS relapses were due to brain metastases (90%
in each group). In addition, a minority was diagnosed with
meningeal carcinomatosis: 20% in the docetaxel-containing
experimental arms and 18% in the control arms. Roughly, one
quarter of patients with CNS relapse had CNS as the only site
of disease at the time of death: 26% in the experimental arms
and 21% in the control arms, further attesting to the
considerable clinical importance of CNS relapse. In 54% and
63% of patients who died and had a prior CNS relapse, the
CNS relapse was considered the main cause of death.
Unexpectedly, the proportion of patients in whom the
diagnosis of CNS relapse was made by magnetic resonance
imaging (MRI) as compared with computed tomography (CT)
scan was somewhat higher in the docetaxel-containing arms
(47% by MRI and 66% by CT) than in the control arms (30%
MRI, 83% CT). This higher use of MRI in the docetaxel-
containing arms would be expected to potentially increase the
detection of CNS relapse in this subpopulation, thus
strengthening the data showing that there was no increased rate
of CNS relapse in the experimental arms. In addition, there was
an unexpected increase in positive cerebrospinal fluid cytology
in the docetaxel-treated patients 8.5% compared with 3.2% in
the control patients. To further elucidate the latter finding, we
reviewed the data on 19 patients in whom a diagnosis of
meningeal carcinomatosis was made (Table 4). This diagnosis
Table 2. Patient population analysed for CNS relapse (N = 403)
Treatment arm Control arms (no T) Experimental arms (T)
Treatment A or AC A–T or AT
n % n %
Patients 968 100 1919 100
Deceased patients 143 14.8 260 13.5
CNS relapse at death 39 4.0 71 3.7
CNS relapse as first site 13 1.3 35 1.8
No CNS relapse at death 99 10.2 184 9.6
CNS relapse of all deaths 39/143 27.2 71/260 27.3
CNS relapse unknown 5/143 4.2 5/260 1.9
CNS relapse in HR+ 15/81 18.5 29/141 20.6
CNS relapse in HR2 24/62 38.7 42/119 35.3
Deceased, HER2 result
available
78/143 54.5 124/260 47.7
Deceased, HER2 available,
CNS-R unknown
2/78 2.6 3/124 2.4
CNS relapse in HER2+ 15/31 48.4 18/33 54.5
CNS relapse in HER22 15/45 33.3 33/88 37.5
CNS relapse in triple-negative
disease
11/19 57.9 18/39 46.2
HER2 positivity was defined as a 3+ intensity staining in at least 30% of
malignant cells by immunohistochemistry. Triple negative disease, ER
negative, PgR negative and HER2 negative. HR positivity was defined as ER
positive or PgR negative.
CNS, central nervous system; T, docetaxel; A, doxorubicin; AC, doxorubicin
plus cyclophosphamide; HR, hormone receptor; ER, oestrogen receptor;
PgR, progesterone receptor.
Table 3. Patients with CNS relapse (N = 110)a
Treatment arms Control (no T) Experimental (T)
Treatment A or AC A–T or AT
n % n %
CNS relapse 39 100 71 100
Neurological symptoms 29/32 91 58/65 90
Brain metastases 34/38 90 61/67 91
Meningeal carcinomatosis 6/34 18 13/64 20
CNS only disease at death 8/38 21 18/68 26
CNS-R main cause of death 24/38 63 37/68 54
CT scan abnormal due to
CNS-R
30/35 86 39/59 66
MRI abnormal due to CNS-R 10/33 30 28/60 47
CSF abnormal due to CNS-R 1/31 3.2 6/59 8.5
aDenominators indicate numbers of patients with information available.
CNS-R, central nervous system relapse; CSF, cerebrospinal fluid; CT,
computed tomography; MRI, magnetic resonance imaging; T, docetaxel; A,
doxorubicin; AC, doxorubicin plus cyclophosphamide.
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was proven by cytology or histology in six in the taxane-treated
patients compared with two in the control patients.
The median survival time for patients after CNS relapse was
4 months, and >80% had died at 1 year (Figure 1). When
comparing survival time after CNS relapse of the patients with
parenchymal brain metastases only (n = 88, 4.0 months) to
patients with meningeal carcinomatosis only (n = 12, 2.6
months), the latter had a significantly worse survival time
(Figure 2) (P = 0.0345). (From this analysis, seven patients with
both brain metastases and meningeal carcinomatosis were
excluded.) Survival for >1 year after CNS relapse was only
observed in the subgroup with parenchymal brain metastases.
discussion
While metastatic breast cancer is usually an incurable disease
regardless of the sites involved with distant metastases, CNS
relapse is a particularly feared scenario. CNS relapse is almost
always accompanied by neurologic symptoms (90% in the
present study). In this study, 25% of patients with CNS relapse
have died without evidence of extra-CNS metastases. Of all the
403 patients who died within 5 years of adjuvant trial entry, 26
(6.8%) had CNS disease as the only site of relapse. Measured
from the time of diagnosis of CNS relapse only, about 20% of
patients survived 1 year and were from the subgroup with
parenchymal brain metastases only. In this regard, our findings
are very consistent with previously published large trials [7].
Similarly, the overall incidence of 4% CNS relapse at 5 years are
consistent with published rates of 3.3% at 5 years and 5.4% at
13 years [7]. In large trials, increased rates of CNS relapse were
seen in node-positive, ER-negative, high-grade, HER2-positive
disease as well as in young patients [7]. Similarly, in our node-
positive population, we have found increased rates of CNS
relapse in ER-negative, HER2-positive and triple-negative
patients. Not surprisingly, after primary chemotherapy for
locally advanced or inflammatory breast cancer, CNS relapse
has been observed somewhat more frequently: in 61 of 769
(7.9%) patients after a 9.5-year follow-up [8] and in 13 of 140
(9.3%) after a 5-year follow-up [9]. In these single-centre series,
similar risk factors for CNS relapse have been described (e.g.
young age, ER-negative tumours). In contradistinction to the
present study, no comparisons between regimens were possible
since a variety of chemotherapy regimens had been employed in
these retrospective studies [8,9].
In recent years, high rates of CNS relapse have been observed
in smaller studies of patients treated with taxane-based (14%
and 30%) [5,6] or with trastuzumab-based (34% and 39%)
[10,11,12] therapy for metastatic breast cancer. The reason for
these higher rates are unknown, although efficacy in the
systemic ‘compartment’ in conjunction with restricted efficacy
of these treatments in the CNS ‘compartment’ [11],
heterogeneity in tumour cell biology [13] and/or drug
interactions with the blood brain barrier can be considered.
Therefore, we decided to analyse CNS relapse in the well-
defined cohorts of the adjuvant BIG 2-98 trial involving
treatment groups with and without a taxane (docetaxel).
Overall, we were unable to identify an association of adjuvant
docetaxel treatment with an increased frequency of CNS
relapse. Around 27% of patients in both groups had CNS
relapse at the time of death. With respect to the HER2 status,
Table 4. Patients with a diagnosis of meningeal carcinomatosis (N = 19)
Control
arms (no T)
Experimental
arms (T)
Number of patients 6 13
Method of diagnosis
By CSF cytology 6 MRI 6 CT 1 5
By histology 6 MRI 6 CT 1 1
By MRI 6 CT 2 4
By CT scan only 2 2
By physical exam only 0 1
Concurrent brain metastases 2 5
CSF, cerebrospinal fluid, CT, computed tomography; MRI, magnetic
resonance imaging; T, docetaxel.
Figure 1. Kaplan-Meier curve with 95% confidence band. This figure was
constructed from 109 of the 110 patients, because for one patient the date
of diagnosis of CNS relapse is unknown.
Figure 2. Kaplan-Meier curves of time from diagnosis of CNS-relapse to
death in patients with brain metastases only (continuous line, N = 88)
compared with patients with meningeal carcinomatosis only (dotted line,
N = 12). The prognosis of the latter group is significantly worse (p =
0.0451).
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our results support the findings from the literature: CNS
relapse was more frequent in deceased patients with HER2-
positive tumours (51.6%) compared with HER2-negative
patients (36.1%). However, in neither HER2 subgroup was
there a difference in CNS relapse rate between the treatment
arms. Therefore, rather than adjuvant docetaxel treatment, it
seems to be the biology of HER2-positive tumours that is
associated with an increased rate of CNS relapse [13]. On the
other hand, it is conceivable that in the future, adjuvant
trastuzumab may influence CNS relapse rates in HER2-positive
breast cancer since trastuzumab does not cross the blood–brain
barrier due to its size [11, 14].
In conclusion, there is no evidence that adjuvant taxane
treatment is associated with an increased frequency of CNS
relapse. A higher incidence of CNS relapse is confirmed for
HER2-positive breast cancer by this prospective study. CNS
relapse continues to have a poor prognosis and more so in case
of meningeal carcinomatosis than brain metastases.
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